Part 1 interim analysis of the ACTION3 Phase 3 clinical trial also confirmed a reduction in proteinuria in the DMX-200 arm compared to placebo after 35 weeks. The trial can therefore continue ...

Credit: H_Ko/Shutterstock. The US Food and Drug Administration (FDA) has confirmed proteinuria as an acceptable primary endpoint in Dimerix ‘s Phase III ACTION3 trial of DMX-200 for treating focal ...